✦ LIBER ✦

630 RIBAVIRIN (RBV) DOSAGE AS INDEPENDENT PREDICTOR OF RVR IN HCV GENOTYPE 2 (HCV-2) AND 3 (HCV-3) PATIENTS UNDERGOING COMBINED TREATMENT WITH PEG INTERFERON (PEG-IFN) ALPHA-2B

✍ Scribed by A. Mangia; O. Dalgard; N. Minerva; H. Verbaan; G. Scotto; D. Bacca; E. Agostinacchio; K. Bjoro; V. Carretta; V. Piazzolla; R. Cozzolongo; M. Romano; L. Mottola; A. Andriulli

Book ID: 117377638
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 49 KB
Volume: 50
Category: Article
ISSN: 0168-8278
DOI: 10.1016/s0168-8278(09)60632-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Individualized treatment with combinatio

Individualized treatment with combination of Peg-interferon alpha 2b and ribavirin in patients infected with HCV genotype 3

✍ Alessandra Mangia; Franco Bandiera; Giuseppe Montalto; Leonardo Mottola; Valeria 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 687 KB

Ribavirin dosage in patients with HCV ge

Ribavirin dosage in patients with HCV genotypes 2 and 3 who completed short therapy with peg-interferon α-2b and ribavirin

✍ A. MANGIA; O. DALGARD; N. MINERVA; H. VERBAAN; D. BACCA; H. RING-LARSEN; M. COPE 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 132 KB

Su1074 Meta-Analysis: Sustained Virologi

Su1074 Meta-Analysis: Sustained Virologic Response (SVR) in Patients With Infection With Hepatitis C Virus Genotype 5 (HCV-5) Versus Genotype 1 (HCV-1) and HCV Genotype 2/3 (HCV -2/3) Treated With Interferon (IFN) or Pegylated Interferon and Ribavirin (PEG IFN+RBV)

✍ Devaki, Pardha; Jencks, David S.; Nangia, Sharad; Marupakula, Vidyasagargoud; Ng 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 609 KB

Early discontinuation of ribavirin in HC

Early discontinuation of ribavirin in HCV genotype 2 and 3 patients undergoing short-treatment duration with Peg-interferon alfa 2a and ribavirin

✍ A. Andriulli; P. Andreone; C. Cursaro; R. Cozzolongo; N. Minerva; A. Iacobellis; 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 58 KB

435 TREATMENT OF HCV GENOTYPE 3 (GT3)-IN

435 TREATMENT OF HCV GENOTYPE 3 (GT3)-INFECTION WITH PEG-IFN A-2B AND RIBAVIRIN (RBV): AGE RELATED DIFFERENCES IN SVR AND RELAPSE

✍ S. Mauss; G. Teuber; E. Zehnter; M.P. Manns; T. Dahhan; U. Meyer; B. Möller; N. 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 42 KB

78 The HCV NS3 protease inhibitor SCH 50

78 The HCV NS3 protease inhibitor SCH 503034 in combination with PEG-IFNα-2b in the treatment of HCV-1 PEG-IFNα-2b non-responders: Antiviral activity and HCV variant analysis

✍ S. Zeuzem; C. Sarrazin; F. Wagner; R. Rouzier; N. Forestier; S. Gupta; M. Hussai 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 102 KB